Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: Cholinergic control of GLP-1 secretion via muscarinic receptors

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 3, 1997, Pages 786-790

  Balks, H J ^a   Holst, J J ^b   Von Zur Muhlen A ^a   Brabant, G ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; GASTRIN; GLUCAGON LIKE PEPTIDE 1; MUSCARINIC RECEPTOR; PANCREAS HORMONE;

ADULT; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; INTESTINE CELL; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN SECRETION;

ADULT; ATROPINE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PARASYMPATHETIC NERVOUS SYSTEM; PEPTIDES; RECEPTORS, MUSCARINIC; TIME FACTORS;

EID: 0031034854     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.3.786     Document Type: Article

References (44)

1. Cataland S, Crockett SE, Brown JC, Mazzaferri EL. 1974 Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab. 39:223-228.
2. Pederson RA, Schubert HE, Brown JC. 1975 Gastric inhibitory polypeptide its physiologic release and insulinotropic action in the dog. Diabetes. 24:1050-1056.
3. Creutzfeldt W, Ebert R. 1977 Release of gastric inhibitory polypeptide (GIP) to a test meal under normal and pathological conditions in man. In: Bajaj JS, ed. Proceedings of the Ninth International Congress of International Diabetes Federation. Amsterdam: Excerpta Medica; 63-75.
4. Fried M, Mayer EA, Bloom SR, Taylor IL, Meyer JH. 1989 GIP and insulin release in relation to gastric emptying of a mixed meal in man. Regul Peptides. 26:305-312.
5. Holst JJ, Ørskov C, Nielsen VO, Schwartz TW. 1987 Truncated glucagon-like peptide-1, an insulin releasing hormone from the distal gut. FEBS Lett. 211:169-174.
6. Kreyman B, Williams G, Ghatei MA, Bloom SR. 1987 Glucagon-like peptide-1(7-36): a physiological incretin in man. Lancet. 2:1300-1304.
7. Komatsu R, Matsuyama T, Namba M, et al. 1989 Glucagonostatic and insulinotropic action of glucagon-like polypeptide I(7-36)amide. Diabetes. 38:902-905.
8. Nauck M, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. 1993 Preserved incretin activity of glucagon-like peptide-1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 91:301-307.
9. Hvidberg A, Nielsen M-BT, Hilsted J, Ørskov C, Holst JJ. 1994 Effect of glucagon-like peptide-1 (proglucagon 78-101 amide) on hepatic glucose production in healthy man. Metabolism. 43:104-108.
10. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. 1993 Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1(7-36)amide in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:741-744.
11. Gutniak M, Ørskov C, Holst JJ, Ahren B, Efendic S. 1992 Antidiabetogenic effect of glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 326:1316-1322.
12. Ørskov C, Wettergren A, Holst JJ. 1993 Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagon-like peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes. 42:658-661.
13. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener J. 1992 Preliminary studies of insulinotropic actions of glucagon-like peptide-I(7-37) administered to diabetic and nondiabetic human subjects. Diabetes Care. 15:270-277.
14. Gutniak MK, Linde B, Efendic S. 1993 Subcutaneous injection of glucagon-like insulinotropic peptide reduces postprandial glycemia in non-insulin-dependent diabetes. Digestion. 54:389-390.
15. Elahi D, McAloon-Dyke M, Fukagawa NK, et al. 1994 The insulinotropic actions of glucose-dependnet insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 51:63-74.
16. Ørskov C, Jeppesen J, Madsbad S, Holst JJ. 1991 Proglucagon products in plasma of non insulin-dependent diabetics and non diabetic controls in the fasting state and after oral glucose and intravenous arginin. J Clin Invest. 87:415-423.
17. Elliot RM, Morgan LM, Tredger JA, Deacon S, Wright J. 1993 Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 138:159-166.
18. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. 1995 Glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide plasma levels in response to nutrients. Digestion. 56:117-126.
19. Larsson LI, Holst JJ, Hakanson R, Sundler F. 1975 Distribution and properties of glucagon immunreactivity in the digestive tract of various mammals: an immunohistochemical and immunochemical study. Histochemistry. 44:281-290.
20. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B. 1992 Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 22:283-291.
21. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. 1993 Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 76:912-917.
22. Roberge JN, Brubaker PL. 1993 Regulation of intestinal proglucagon-drived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology. 133:233-240.
23. Brubaker PL. 1991 Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology. 128:3175-3182.
24. Abello J, Ye F, Bosshard A, Bernard C, Cuber JC, Chayvialle JA. 1994 Stimulation of glucagon-like peptide-1 secretion by muscarinic agonist in a murine intestinal endocrine cell line. Endocrinology. 134:2011-2017.
25. Balks HJ, Schmidt A, Prank K, Hemmer F, Von zur Mühlen A, Brabant G. 1992 Temporal pattern of pancreatic insulin and C-peptide secretion and of plasma glucose levels after nutritional stimulation. J Clin Endocrinol Metab. 75:1198-1203.
26. Ørskov C, Holst JJ. 1987 Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 47:165-174.
27. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. 1994 Tissue and plasma concentrations of amidated and glycine extended glucagon-like peptide-1 in humans. Diabetes. 43:535-539.
28. Brabant G, Prank K, Ranft U, Schuermeyer T, Wagner TOF, Hauser H, Kummer B, Feistner H, Hesch RD, Von zur Mühlen A. 1990 Physiological regulation of circadian and pulsatile thyrotropin secretion in normal men and woman. J Clin Endocrinol Metab. 70:403-409.
29. Deacon CF, Johnson AH, Holst JJ. 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 80:952-957.
30. Merriam GR, Wachter KW. 1982 Algorythms for the study of episodic hormone secretion. Am J Physiol. 243:E310-E318.
31. Dixon WJ, ed. 1981 BMDP statistical software; program IT. Berkley: University of California Press.
32. Jaspan JB, Lever E, Polonsky KS, Van Cauter E. 1986 In vivo pulsatility of pancreatic islet peptides. Am J Physiol. 251:E215-E226.
33. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 44:1126-1131.
34. D'Alessio DA, Fujimoto WY, Ensinck JW. 1989 Effects of glucagon-like polypeptide I(7-36) on the release of insulin, glucagon and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes. 38:1534-1538.
35. Cooke AR. 1975 Control of gastric emptying and motility. Gastroenterology. 68:804-816.
36. Frohman LA, Bernardis LL. 1971 Effect of hypothalamic stimulation on plasma glucose, insulin and glucagon levels. Am J Physiol. 221:1596-1603.
37. Gerich JE, Lorenzi M. 1978 The role of the autonomic nervous system and somatostatin in the control of insulin and glucagon secretion. Front Neuroendocrinol. 5:265-288.
38. Hedo JA, Villanueva ML, Marco J. 1978 Stimulation of pancreatic polypeptide and glucagon secretion by 2-deoxy-D-glucose in man: evidence for cholinergic mediation. J Clin Endocrinol Metab. 47:366-371.
39. Herrmann-Rinke C, Vöge A, Hess M, Göke B. 1995 Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol. 147:25-31.
40. Creutzfeldt W. 1979 The incretin concept today. Diabetologia. 16:75-85.
41. Larrimer JN, Mazzaferri EL, Cataland S, Mekhjian HS. 1978 The effect of atropine on glucose-stimulated gastric inhibitory polypeptide. Diabetes. 27:638-642.
42. Stagner JE, Samols W, Weir GC. 1980 Sustained oscillations of insulin, glucagon and somatostatin from the isolated canine pancreas during exposure to a constant glucose concentration. J Clin Invest. 65:939-942.
43. O'Meara NM, Sturis J, Blackman JD, et al. 1993 Oscillatory insulin secretion after pancreas transplant. Diabetes. 42:855-861.
44. Porksen N, Munn S, Ferguson D, O'Brien T, Veldhuis J, Butler P. 1994 Coordinate pulsatile insulin secretion by chronic intraportally transplanted islets in the isolated perfused rat liver. J Clin Invest. 94:219-227.